Russia's Allergard allergy vaccine to enter civilian use in October

Russia's FMBA announced that the Allergard vaccine for birch pollen and cross-reactive food allergies will enter civilian use in October. This marks a notable advancement in allergy treatment, though details on efficacy, distribution, and regulatory approval remain limited. The development is significant for Russia's public health landscape but has limited immediate global market impact.